Deals
Allergan Weighs Options for Women's Health Unit
- Company talks with adviser on possible $5 billion-plus sale
- Stock has fallen 33 percent in past year amid competitive risk
This article is for subscribers only.
Allergan Plc, which has been looking for ways to counter its stock slump as new threats to its top-selling skin and eye drugs have emerged, is considering options for its women’s health unit, according to people with knowledge of the matter.
The specialty pharmaceuticals product maker has held talks with advisers about strategic options for the unit, including a sale, said the people, who asked not to be identified because they weren’t authorized to speak publicly. A sale, which would likely to attract interest from private equity firms, could value the business at more than $5 billion, the people said.